Contact this trialFirst, we need to learn more about you.
Cyclin-dependent kinase (CDK) inhibitor
Xentuzumab + Abemaciclib for Breast Cancer
Recruiting1 awardPhase 1
Santa Monica, California
This trial is testing the combination of two drugs, xentuzumab and abemaciclib, to see if they are safe and effective at shrinking tumors in patients with lung and breast cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service